Work

Abstract 915: Expanded biomarker results from a phase I dose escalation study of GDC-0032, a beta isoform-sparing PI3K inhibitor

Year: 2014

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2014-915

Authors: Timothy R. Wilson, Heidi Savage, Carol O'Brien, Sandra Sanabria, Ray S. Lin, Marie-Claire Wagle, Yibing Yan, Mark R. Lackner, Hema Parmar, Jerry Y. Hsu, Dejan Juric, Ian E. Krop, Ramesh K. Ramanathan, Daniel D. Von Hoff, Jose Baselga

Institutions: Genentech, Massachusetts General Hospital, Dana-Farber Cancer Institute, Translational Genomics Research Institute, Memorial Sloan Kettering Cancer Center

Language: English

Topic: PI3K/AKT/mTOR signaling in cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W1589440099

Cites:

Cited by:

Related to: 10